The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study
Keywords: clear or almost clear skin; clinical trial; phase 3; prospective; scalp psoriasis; secukinumab; Psoriasis Scalp Severity Index; AEs; adverse events; BSA; body surface area; CI; confidence interval; IGA mod 2011; Investigator's Global Assessment modified 2